source
- Johnson & Johnson shares drop 6% after earnings meet forecasts but show weak medical device outlookJohnson & Johnson reported third‑quarter results that met Wall Street expectations and raised its 2026 financial guidance, yet the stock fell about 6% on the day. Analysts highlighted an underwhel…
- Zealand Pharma to invest up to $1.2 billion in Generate’s AI platform for obesity drug developmentZealand Pharma announced a partnership with Generate:Biomedicines to use the latter's generative‑AI platform for creating new multispecific drug candidates aimed at obesity and metabolic disorders.…